Today I’m looking at four FTSE 100 (INDEXFTSE: UKX) plays dealing at ridiculous prices!
Post a fortune
I’m convinced that exploding online shopping activity bodes well for Britain’s oldest courier Royal Mail (LSE: RMG), as it’s a phenomenon that should keep blasting parcel volumes higher at home and across the continent.
The City expects earnings at Royal Mail to dip 5% in the year to March 2017 as the impact of huge restructuring weighs. Still, this leaves the business dealing on a terrific P/E rating of 12.6 times. And this reading slips to 12.5 times for 2018 thanks to a predicted 3% earnings advance.
And dividend seekers should be interested in estimated rewards of 23p and 24p per share for 2017 and 2018, respectively, figures that yield 4.3% and 4.5%.
Engineer a fortune
Investor appetite for GKN (LSE: GKN) has been numbed in recent times by weakening demand for its agricultural and aerospace products. However, I’m convinced the long-term outlook for the engineer’s critical marketplaces remains solid, particularly at the firm’s GKN Driveline car division.
Consequently a P/E rating of 9.7 times for 2016 is exceptional value, in my opinion, despite an anticipated 1% drop for the current period. Indeed, GKN’s growth story is anticipated to get back on track from 2017, when an anticipated 8% bottom-line advance pushes the multiple to just 9.1 times.
Meanwhile, predicted dividends of 9.1p and 9.6p per share for this year and next yield a handy 3.3% and 3.5%, respectively.
Defence darling
With Western defence budgets heading back in the right direction, I believe the earnings picture at BAE Systems (LSE: BA) is in great shape. On top of this, the arms builder is also enjoying rising demand from non-US and UK customers, and I expect this to keep rising along with galloping wealth levels in these hot new regions.
BAE Systems is expected to endure a 4% earnings dip in 2016 due to near-term contract timing issues. But a 7% rebound is predicted for 2017. As a consequence BAE Systems deals on decent P/E ratios of 12.3 times and 11.6 times for these years.
And anticipated dividends of 21.4p per share for 2016 and 22p for next year yield a handsome 4.4% and 4.6%, respectively.
Medicines marvel
Although a battered growth pick in recent times, I believe that GlaxoSmithKline’s (LSE: GSK) efforts to rejuvenate its product pipeline should get earnings firing again from this year onwards, and put an end to the enduring impact of patent losses on revenues expansion.
This view is shared by the City, and the bottom line is expected to advance 16% this year and 4% in 2017. These figures leave GlaxoSmithKline dealing on reasonable P/E ratings of 16.3 times and 15.8 times for these years.
But it’s in the dividend stakes where the pharma giant really sets itself apart, with a planned 80p-per-share dividend for this year and next yielding a smashing 5.4%.